TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
Status:
Not yet recruiting
Trial end date:
2024-05-20
Target enrollment:
Participant gender:
Summary
This is An Open, Single Arm, Multicenter, Exploratory Phase II study, to evaluate the
efficacy and safety of TQB2450 Plus anlotinib as adjuvant therapy in hepatocellular
carcinoma(HCC) patients at high risk of recurrence after resection. The patients who are
confirmed by Histology or cytology as HCC with high-risk recurrence after R0 liver resection
will be enrolled. 18 cycles adjuvant treatment with TQB2450 Plus anlotinib can improve
one-year recurrence free survival (RFS) rate of HCC patients after R0 surgical resection.